DAWN
Day One Biopharmaceuticals, Inc. [DAWN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DAWN Stock Summary
Top 10 Correlated ETFs
DAWN
Top 10 Correlated Stocks
DAWN
In the News
DAWN Financial details
Company Rating
-
Market Cap
1.2B
Income
-181.9M
Revenue
560K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
155
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-7.68
Forward P/E
-
PEG
-6.46
P/S
-
P/B
-3.08
P/C
-
P/FCF
-8.76
Quick Ratio
16.57
Current Ratio
16.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.26
EPS next Y
-
EPS next Q
-
EPS this Y
17.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.81%
-
-
-
-
SMA20
-0.17%
SMA50
-11.7%
SMA100
-14.93%
Inst Own
-
Inst Trans
-
ROA
-39%
ROE
-1546%
ROC
-0.49%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.67-17.85
52W High
-26.88%
52W Low
+38.11%
RSI
52.15
Rel Volume
1.18
Avg Volume
636.27K
Volume
752.53K
Perf Week
4.28%
Perf Month
0.24%
Perf Quarter
-11.34%
Perf Half Y
-12.46%
-
-
-
-
Beta
-1.481
-
-
Volatility
0.2%, 0.41%
Prev Close
1.64%
Price
12.43
Change
5.7%
Company Profile
- Volume Average 636.27K
- Market Capitalization 1.2B
- Employee 155
- CEO Dr. Jeremy Bender M.B.A., Ph.D.
- Headquarters South San Francisco,CA,US
- IPO Date 2021-05-27
-
Website
https://dayonebio.com 
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
